Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Exemestane|DRUG: Sutent
Sponsor: Baylor Breast Care Center
Collaborators: Pfizer